Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: The need for predictors and indicators of effectiveness has not abated

British Journal of Haematology

Volumn 142, Issue 1, 2008, Pages 3-10

  Katodritou, Eirini ^a   Zervas, Konstantinos ^a   Terpos, Evangelos ^b   Brugnara, Carlo ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer related anaemia; Erythropoiesis stimulating agents; Intravenous iron; Predictive markers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DEXAMETHASONE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ANEMIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTINUOUS INFUSION; DRUG EFFICACY; ERYTHROID CELL; FERRITIN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; IRON BALANCE; IRON DEFICIENCY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANEMIA; ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; NEOPLASMS;

EID: 44649144778     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07163.x     Document Type: Review

References (74)

1. Ahluwalia, N. (1997) Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. American Journal of Kidney Diseases, 30, 532 541.
2. Auerbach, M., Ballard, H., Trout, R., Mellwain, M., Ackerman, A., Balirain, H., Balan, S., Barker, L. Rana, J. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology, 22, 1301 1307.
3. Auerbach, M., Ballard, H. Glaspy, J. (2007) Clinical update: intravenous iron for anaemia. The Lancet, 369, 1502 1504.
4. Bailie, G.R. (2005) Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology, Dialysis, Transplantation, 20, 1443 1449.
5. Bastit, L., Vanderbroek, A., Altintas, S., Gaede, B., Pinter, T., Suto, T.S., Mossman, T.W., Smith, K.E. Vasteenkiste, J.F. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Journal of Clinical Oncology, 26, 1611 1618.
6. Beamish, M.R., Davies, A.G., Eakins, J.D., Jacobs, A. Trevett, D. (1971) The measurement of reticuloendothelial iron release using iron-dextran. British Journal of Haematology, 21, 617 622.
7. Beguin, Y. (1995) Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. British Journal of Haematoogy, 89, 17 23.
8. Beguin, Y. (2005) Intravenous iron and recombinant human erythropoietin in cancer patients. Journal of Clinical Oncology, 23, 651 652.
9. Bennett, C.L., Silver, S.M., Djulbegovic, B., Samaras, A.T., Blau, C.A., Gleason, K.J., Barnato, S.E., Elverman, K.M., Courtney, D.M., McKoy, J.M., Edwards, B.J., Tigue, C.C., Raisch, D.W., Yarnold, P.R., Dorr, D.A., Kuzel, T.M., Tallman, M.S., Trifilio, S.M., West, D.P., Lai, S.Y. Henke, M. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: the journal of the American Medical Association, 27, 914 924.
10. Bohlius, J., Wilson, J., Seidelfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., Bennett, C.L., Langensiepen, S., Hyde, C. Engert, A. (2006) Recombinant human erythropoietin in cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98, 708 714.
11. Bokemeyer, C., Aapro, M.S., Courdi, A., Foubertd, J., Linke, H., Osterborg, A., Repetto, L. Soubeyran, B. (2007) EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258 270.
12. Bovy, C., Gothot, A., Delanaye, P., Warling, X., Krzesinski, J.M. Beguin, Y. (2007) Mature erythrocyte parameters as new markers of functional iron deficiency in hemodialysis: sensitivity and specificity. Nephrology, Dialysis, Transplantation, 22, 1156 1162.
13. Brugnara, C. (2000) Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Critical Reviews in Clinical Laboratory Sciences, 37, 93 130.
14. Brugnara, C. (2003) Iron deficiency and erythropoiesis: new diagnostic approaches. Clinical Chemistry, 49, 1573 1578.
15. Brugnara, C., Schiller, B. Moran, J. (2006) Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clinical and Laboratory Haematology, 28, 303 308.
16. Cavill, I. (2002) Erythropoiesis and iron. Best Practice & Research. Clinical Hematology, 15, 399 409.
17. Cavill, I., Auerbach, M., Bailie, G., Barrett-Lee, P., Kaltwasser, P., Littlewood, T., Macdougal, I.C. Wilson, K. (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22, 731 737.
18. Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimoni, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A., Jager, G., LeMevel, A., Najman, A., Silingardi, V., Spriano, M., van Hoof, A. Ehmer, B. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 86, 4446 4453.
19. Cazzola, M., Ponchio, L., Pedrotti, C., Farina, G., Cerani, P., Lucotti, C., Novella, A., Rovati, A., Bergamaschi, G. Beguin, Y. (1996) Prediction of response to recombinant human erythropoietin in anemia of malignancy. Haematologica, 81, 434 441.
20. Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I. Coiffier, B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122, 386 393.
21. Chang, J., Bird, R., Clague, A. Carter, A. (2007) Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients. Pathology, 39, 349 353.
22. Charytan, C., Qunibi, W. Bailie, G.R. (2005) Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. Clinical Practice, 100, 55 62.
23. Chertow, G.M., Mason, P.D., Vaage-Nielsen, O. Ahlmen, J. (2006) Update on adverse drug events associated with parenteral iron. Nephrology, Dialysis, Transplantation, 21, 378 382.
24. Collins, H.L. (2003) The role of iron in infections with intracellular bacteria. Immunology Letters, 85, 193 195.
25. Coyne, D. (2006) Iron indices: what do they really mean? Kidney International, 69, 4 8.
26. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. Adamson, J.W. (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine, 316, 73 78.
27. Fishbane, S., Frei, G.L. Maesaka, J. (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases, 26, 41 46.
28. Fishbane, S., Ungureanu, V.D., Maesaka, J.K., Kaupke, C.J., Lim, V. Wish, J. (1996) The safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Diseases, 28, 529 534.
29. Fishbane, S., Galgano, S., Langley, R., Canfield, W. Maesaka, J.K. (1997) Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney International, 52, 217 222.
30. Glaspy, J.A. (2002) The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park), 16, 35 40.
31. Glaspy, J., Bukowski, R., Steinberg, D., Taylo, C., Tchekmedyian, S. Vadhan-Raj, D. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology, 15, 1218 1234.
32. Goldberg, P. (2007) Danish researchers post long-awaited Aranesp results - ever so discreetly. Cancer Letters, 33, 1 6.
33. Goodnough, L.T. (2007) Erythropoietin and iron-restricted erythropoiesis. Experimental Hematology, 35, 167 172.
34. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schiperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcaham, J., Rossi, G. Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394 403.
35. Hedenus, M., Birgegard, G., Nasman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Larfars, G. Osterborg, A. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 21, 627 632.
36. Hellstrom-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology, 89, 67 71.
37. Hellstrom-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A. Greenberg, P. (1997) Erythroid response to treatment with G-CSF plus erythropoietin for anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344 351.
38. Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. The Lancet, 362, 1255 1260.
39. Henke, M., Mattern, D., Pepe, M., Bezay, C., Weissenberger, C., Werner, M. Pajonk, F. (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? Journal of Clinical Oncology, 24, 4708 4713.
40. Henry, D., Abels, R. Larholt, K. (1995) Prediction of response to recombinant human erythropoietin (r-huEPO/Epoietin a) in cancer patients. Blood, 85, 1676 1678.
41. Henry, D.H., Dahl, N.V., Auerbach, M., Tchekmedyian, S. Laufman, L.R. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist, 12, 231 242.
42. Huang, X. (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutation Research, 533, 153 171.
43. Hudson, J.Q. Comstock, T.J. (2001) Considerations for optimal iron use for anemia due to chronic kidney disease. Clinical Therapy, 23, 1637 1671.
44. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology, 103, 1070 1074.
45. Johnson, D.W., Herzig, K.A., Gissane, R., Campbell, S.B., Hawley, C.M. Isbel, N.M. (2001) Oral versus intravenous iron supplementation in peritoneal dialysis patients. Peritoneal Dialysis International, 21, 231 235.
46. Katodritou, E., Speletas, M., Zervas, K., Kapetanos, D., Georgiou, E., Christoforidou, A., Pavlitou, A., Sion, M. Christakis, J. (2006) Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Laboratory Hematology, 12, 47 54.
47. Katodritou, E., Zervas, K., Speletas, M., Kapetanos, D., Kartsios, C., Verrou, E., Banti, A., Effraimidou, S. Christakis, J. (2007a) Hypochromic erythrocytes (%): a reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Annals of Hematology, 86, 369 376.
48. Katodritou, E., Verrou, E., Kapetanos, D., Bant, A., Kartsios, C., Mihou, D., Gastari, V., Markala, D., Effraimidou, S., Lazaridou, A., Terpos, E. Zervas, K. (2007b) Sequential monitoring of erythrocyte hemoglobinization and iron markers during RHu-EPO therapy in anemic patients with multiple myeloma and lymphoma. Haematologica, 92 (Suppl. 1 28.
49. Laugsch, M., Metzen, E., Svensson, T., Depping, R. Jelkmann, W. (2007) Lack of functional erythropoietin receptors of cancer cell lines. International Journal of Cancer, 22, 1005 1011.
50. Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., Biakhov, M., Valuckas, K., Voznyi, E., Liu, X. Vercammen, E. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology, 23, 5960 5972.
51. Littlewood, T. (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. The Oncologist, 8, 99 107.
52. Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy. Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865 2874.
53. Ludwig, H. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine, 322, 1693 1699.
54. Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H. Schuster, J. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood, 84, 1056 1063.
55. Macdougall, I.C., Cavill, I., Hulme, B., Bain, B., McGregor, B., MacKay, P., Sanders, E., Coles, G.A. Williams, J.D. (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. British Medical Journal, 304, 25 26.
56. Oncologic Drugs Advisory Committee (2007) Continuing Reassessment of the Risks of Erythropoiesis-stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy. Food and Drug Administration, Rockville, MD, 10 May 2007 (Accessed 25 May, 2007, at http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4301b2-00-index.htm).
57. Osterborg, A., Boogaerts, M.A., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A. Peest, D. (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood, 87, 2675 2682.
58. Osterborg, A., Brandberg, Y. Hedenus., M. (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British Journal of Haematology, 129, 206 209.
59. Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.T., Cheze, S., Mahe, B., Ferrant, A., Ravoet, C., Escoffre-Barbe, M., Ades, L., Vey, N., Aljassem, L., Stamatoullas, A., Mannone, L., Dombret, H., Bourgeois, K., Greenberg, P., Fenaux, P., Dreyfus, F., for the GFM group 2008) Predictive factors for response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 111, 574 582.
60. Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Blanchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., Fornarini, G., Pozzi, P., Fabi, A., Labianca, R., Di Costanzo, F., Secondino, S., Crucitta, E., Apolloni, F., Del Santo, A. Siena, S. (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology, 26, 1619 1625.
61. Pettersson, T., Teppo, A.M. Silmes, M.A. (1996) Circulating transferrin receptor during erythropoietin medication of anemic patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 25, 321 324.
62. Rizzo, J.D., Somerfield, M.R., Hagerty, K.L., Seidenfeld, J., Bohlius, J., Bennett, C.L., Cella, D.F., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Rarick, M.U., Regan, D.H. Lichtin, A.E. (2008) American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. Journal of Clinical Oncology, 26, 132 149.
63. Sengölge, G., Horl, W.H. Sunder-Plassmann, G. (2005) Intravenous iron therapy: well-tolerated, yet not harmless. European Journal of Clinical Investigation, 35 (Suppl. 3 46 51.
64. Siedenfeld, J., Piper, M., Flamm, C., Hasselblad, V., Armitage, J.O., Bennett, C.L., Gordon, M.S., Lictin, A.E., Wade, III., J.L., Woolf, S. Aronson, N. (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. Journal of the National Cancer Institute, 93, 1204 1214.
65. Sinclair, A.M., Todd, M.D., Forsythe, K., Knox, S.J., Elliot, S. Begley, C.G. (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer, 110, 477 488.
66. Steinmetz, T., Hellmoch, M., Neise, M., Aldaud, A., Lerchenmuller, C., Tsamaloukas, A., Fandel, F., Weiligmann, C., Totzke, U. Schmitz, S. (2007) Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist, 12, 748 755.
67. Sullivan, J.L. (2004) Is stored iron safe? The Journal of Laboratory and Clinical Medicine, 144, 280 284.
68. Sullivan, J. (2007) Long-term risks of increased use of intravenous iron. The Lancet, 370, 481 482.
69. Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michalis, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, N.P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J.I., Meletis, J., Bourantas, K.L., Zoumbos, N.C., Yataganas, X. Viniou, N.A. (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174 189.
70. Tessitore, N., Solero, G.P., Lippi, G., Bassi, A., Faccini, G.B., Bedogna, V., Gammaro, L., Brocco, G., Restivo, G., Bernich, P., Lupo, A. Maschio, G. (2001) The role of iron status markers in predicting response to intravenous iron in hemodialysis patients. Nephrology, Dialysis, Transplantation, 16, 1416 1423.
71. Thomas, C. Thomas, L. (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clinical Chemistry, 48, 1066 1076.
72. Weiss, G. Goodnough, L. (2005) Anemia of chronic disease. New England Journal of Medicine, 352, 1011 1023.
73. Weiss, G. Gordeuk, V.R. (2005) Benefits and risks of iron therapy for chronic anaemias. European Journal of Clinical Investigation, 35, 36 45.
74. Wright, J.R., Yng, Y.C., Julian, J.A., Pritchard, K.I., Whelan, T.J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., Gagnon, B., Okawara, G.S. Levine, M.N. (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology, 25, 1027 1032.